These findings indicate that WDL selectivity induces caspase-dependent apoptosis in prostate cancer cells via a novel mechanism involving inhibition of PKCε but without inhibition of Akt and suggest that WDL should be tested further as a novel candidate drug for development of an effective therapy against clinical prostate cancer. Here, PRKCE is linked to Familial prostate cancer.